ArticleOpen forum infectious diseases2023
Distribution, Trends, and Antimicrobial Susceptibility of
Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Mass azithromycin distribution and antibiotic resistance in the gut and nasopharynx: a cluster-randomized trial.Nature medicine · 2026Trial
- Effect of adding metronidazole to meropenem on clinical efficacy in complicated intra-abdominal infections: a retrospective study.BMC infectious diseases · 2026Article
- Clinical Emergence ofOpen forum infectious diseases · 2026Article
- Fusobacterium in the microbiome: from health to disease across the oral-gut axis and beyond.NPJ biofilms and microbiomes · 2025Review
- Anaerobic gut bacteria and their potential role in the initiation, exacerbation, and development of human colorectal cancer: a narrative review.Frontiers in cellular and infection microbiology · 2025Review
- Association ofGut microbiome (Cambridge, England) · 2025Review
- Canada's 2025 AMR priority pathogens: Evidence-based ranking and public health implications.PloS one · 2025Article
- Clinical characteristics and antimicrobial susceptibility of Fusobacterium species isolated over 10 years at a Japanese university hospital.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Epidemiology and Clinical Outcomes ofMedicina (Kaunas, Lithuania) · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The increasing prevalence of anaerobic bacteremia is a major concern worldwide and requires longitudinal monitoring. Methods: We present one of the largest and longest longitudinal studies on the prevalence and antimicrobial resistance of Results: Data for 41 949 Conclusions: Our comprehensive national surveillance data analysis demonstrated a continuous increase in the incidence of anaerobic bacteremia, particularly in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.